Price$294.70-11.28 (-3.69%)
01:30 PM07:45 PM
News · 26 weeks78-69%
2025-11-022026-04-26
Mix5790d
- Insider31(54%)
- Other13(23%)
- SEC Filings8(14%)
- Analyst2(4%)
- Leadership2(4%)
- Dividends1(2%)
Latest news
25 items- PRStryker to participate in the Bank of America Securities 2026 Global Healthcare ConferencePortage, Michigan, May 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Spencer Stiles, President and Chief Operating Officer, Jason Beach, Vice President, Group Chief Financial Officer, MedSurg and Neurotechnology and Nick Mead, Vice President, Investor Relations. Their presentation is scheduled for 1:40 p.m. Pacific Time. A live webcast and replay of the presentation will be accessible on Stryker's website at www.stryker.com, and it will be archived on the Investor Relations page. About Stryke
- SECStryker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - STRYKER CORP (0000310764) (Filer)
- PRStryker reports first quarter 2026 operating resultsPortage, Michigan, April 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2026: First Quarter Results Reported net sales increased 2.6% to $6.0 billionOrganic net sales increased 2.4%Reported operating income margin of 15.5%Adjusted operating income margin(1) contracted 180 bps to 21.1%Reported EPS increased 14.2% to $1.93 Adjusted EPS(1) decreased 8.5% to $2.60 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology 5.0 % 1.4 % 3.6 % 2.7 % 0.9 %Orthopaedics
- PRBerger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)PHILADELPHIA, April 24, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC advises shareholders of Stryker Corporation (NYSE:SYK) ("Stryker" or the "Company") about an investigation into Stryker's Board of Directors (the "Board") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation focuses on whether the Board failed to exercise appropriate oversight regarding its cybersecurity and data protection practices, including the Company's response to a recent cyber incident affecting its operations and data environment. Shareholders of Stryker may learn more about this investigation by contacting Berger Montague: Andrew Abr
- PRBerger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)PHILADELPHIA, April 16, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC advises shareholders of Stryker Corporation (NYSE:SYK) ("Stryker" or the "Company") about an investigation into Stryker's Board of Directors (the "Board") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation focuses on whether the Board failed to exercise appropriate oversight regarding its cybersecurity and data protection practices, including the Company's response to a recent cyber incident affecting its operations and data environment.
- ANALYSTLeerink Partners initiated coverage on Stryker with a new price targetLeerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00
- PRStryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolioPortage, Michigan, April 13, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that it has signed a definitive agreement to acquire Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat calcified peripheral arterial disease. The acquisition will strengthen Stryker's Peripheral Vascular (PV) portfolio by adding revascularization technology. Once cleared for use in applicable markets, the product will complement Stryker's existing PV offerings and support the company's strategy to expand its presence in arterial disease treatment
- SECAmendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure8-K/A - STRYKER CORP (0000310764) (Filer)
- PRStryker to announce financial results for its first quarter of fiscal year 2026Portage, Michigan, April 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its first quarter of fiscal year 2026 on Thursday, April 30, 2026. A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's first quarter that ended March 31, 2026. Stryker will host a webcast at 4:30 p.m. ET on Thursday, April 30, 2026, to discuss its first quarter 2026 results. The webcast can be accessed at Stryker - Events & Presentations. An archive of the webcast will also be available on the company's website two hours afte
- PRStryker names Nick Mead Vice President, Investor RelationsPortage, Michigan, March 31, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Nick Mead has been appointed Vice President, Investor Relations, effective May 1, 2026. Mead has nearly 20 years of experience at Stryker, with leadership roles spanning multiple divisions and business units across the company. Most recently, he served as Vice President, Finance for Stryker's Medical division, where he partnered closely with senior leaders to support commercial strategy, capital allocation and operational execution. "Nick brings deep institutional knowledge, strong financial expertise and a proven ability to support strategic decision making
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stryker CorporationSCHEDULE 13G/A - STRYKER CORP (0000310764) (Subject)
- INSIDERSEC Form 4 filed by Stiles Spencer S4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Pierce James Andrew4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Menon Viju4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Lobo Kevin4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Fletcher Robert S4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Fink M Kathryn4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Wells Preston Wendell4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Crotty Dylan Bram4 - STRYKER CORP (0000310764) (Issuer)
- INSIDERSEC Form 4 filed by Berry William E Jr4 - STRYKER CORP (0000310764) (Issuer)
- PRStryker announces Annual Meeting of ShareholdersPortage, Michigan, March 23, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2026 Annual Meeting of Shareholders is scheduled as follows: Wednesday, May 6, 2026 – 12:00 p.m. Eastern Time The Meeting will be held virtually via the internet. Information about the webcast, which will include both the audio and the slide presentation from the meeting, is available on the Investor Relations page of our website at www.investorevents.stryker.com. A recording of the annual meeting will also be available from 10:30 a.m., Eastern Time, on Thursday, May 7, 2026 at www.virtualshareholdermeeting.com/SYK2026 until the definitive proxy statement for our 2027 Annual Meeting of Shareholders is
- SECSEC Form DEFA14A filed by Stryker CorporationDEFA14A - STRYKER CORP (0000310764) (Filer)
- SECSEC Form DEF 14A filed by Stryker CorporationDEF 14A - STRYKER CORP (0000310764) (Filer)
- SECSEC Form 8-K filed by Stryker Corporation8-K - STRYKER CORP (0000310764) (Filer)
- PRGE HealthCare appoints medtech leader Kevin Lobo to Board of DirectorsGE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s
SYK FAQ
7 questionsWhat does Stryker Corporation do?
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various...Where does SYK stock trade?
Stryker Corporation (SYK) is listed on NYSE.What sector and industry is SYK in?
Stryker Corporation operates in the Health Care sector, Medical/Dental Instruments industry.Does SYK pay a dividend?
SYK's most recent ex-dividend date was 2026-03-31 with a cash dividend of $0.88 per share. No future ex-date is on file yet.What are analysts saying about SYK?
Stryker Corporation has had 8 recent analyst actions on file. The most recent action was from Leerink Partners: Outperform on 2026-04-13.What companies are similar to SYK?
Notable peers in the same industry include JNJ (Johnson & Johnson), MDT (Medtronic plc.), BDX (Becton Dickinson and Company), ZBH (Zimmer Biomet Holdings Inc.), BAX (Baxter International Inc.). Compare SYK side-by-side with any of them on Quantisnow.How can I track SYK on Quantisnow?
Quantisnow aggregates Stryker Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SYK to receive live email and push alerts on every new disclosure.